Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Sweeney, Christopher J."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.
    Autorzy:
    Rudman SM; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
    Gray KP; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA.
    Batista JL; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, Boston, MA, USA.; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
    Pitt MJ; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
    Giovannucci EL; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, Boston, MA, USA.; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA.; Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
    Harper PG; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
    Loda M; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
    Mucci LA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, Boston, MA, USA.; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
    Sweeney CJ; Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2016 Dec; Vol. 118 (6), pp. 919-926. Date of Electronic Publication: 2016 Mar 08.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Androgen Antagonists/*therapeutic use
    Neoplasm Recurrence, Local/*mortality
    Neoplasm Recurrence, Local/*therapy
    Prostatic Neoplasms/*mortality
    Prostatic Neoplasms/*therapy
    Aged ; Aged, 80 and over ; Humans ; Male ; Metabolic Diseases/complications ; Middle Aged ; Neoplasm Recurrence, Local/blood ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/complications ; Risk Assessment
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
    Autorzy:
    Ziehr DR; Harvard Medical School, Boston, MA, USA.
    Chen MH; Department of Statistics, University of Connecticut, Storrs, CT, USA.
    Zhang D; Department of Statistics, University of Connecticut, Storrs, CT, USA.
    Braccioforte MH; Prostate Cancer Foundation of Chicago, Westmont, IL, USA.
    Moran BJ; Prostate Cancer Foundation of Chicago, Westmont, IL, USA.
    Mahal BA; Harvard Medical School, Boston, MA, USA.
    Hyatt AS; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Houston, TX, USA.
    Basaria SS; Department of Endocrinology, Brigham and Women's Hospital, Houston, TX, USA.
    Beard CJ; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Houston, TX, USA.
    Beckman JA; Department of Cardiology, Brigham and Women's Hospital, Houston, TX, USA.
    Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Houston, TX, USA.
    D'Amico AV; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Houston, TX, USA.
    Hoffman KE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Hu JC; Department of Urology, The University of California Los Angeles (UCLA) Medical Center, Los Angeles, CA, USA.
    Martin NE; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Houston, TX, USA.
    Sweeney CJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Houston, TX, USA.
    Trinh QD; Division of Urology, Brigham and Women's Hospital, Houston, TX, USA.
    Nguyen PL; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Houston, TX, USA.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2015 Sep; Vol. 116 (3), pp. 358-65. Date of Electronic Publication: 2014 Oct 29.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Androgen Antagonists/*adverse effects
    Antineoplastic Agents, Hormonal/*adverse effects
    Coronary Disease/*mortality
    Prostatic Neoplasms/*drug therapy
    Prostatic Neoplasms/*mortality
    Aged ; Aged, 80 and over ; Androgen Antagonists/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Goserelin/adverse effects ; Goserelin/therapeutic use ; Humans ; Leuprolide/adverse effects ; Leuprolide/therapeutic use ; Male ; Middle Aged ; Prostatic Neoplasms/epidemiology ; Retrospective Studies ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies